Skip to main content

Table 1 Baseline demographic and clinicopathological characteristics

From: Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases

Characteristic

USC ( N= 15)

PTR ( N= 42)

P value

Follow-up duration (months)

13.4 (11.3 to 23.2)

19.2 (12.4 to 28.9)

0.232

Age (years)

63 (48 to 65)

61.5 (54 to 70.5)

0.568

Sex

Male

7

8

0.048

 

Female

8

34

 

BMI (kg/m2)

21.2 (16.9 to 25.5)

21.4 (19.8 to 23.1)

0.978

Performance status

0

14

39

1.00

 

1

1

3

 
 

≥2

0

0

 

ASA score

1

3

10

0.949

 

2

11

29

 
 

3

1

3

 
 

4

0

0

 

Primary tumor site

Right colon

1

13

0.005

 

Left colon

3

18

 
 

Rectum

11

11

 

KRAS status

Wild type

6

24

0.368

 

Mutant or unknown

9

18

 

CEA

23.1 (4.1 to 60.3)

41.5 (12.9 to 344)

0.074

Invasion depth

T2

0

1

0.337

 

T3

6

17

 
 

T4a

9

20

 
 

T4b

0

4

 

Lymph node metastasis

Negative

1

5

1.00

 

Positive

14

37

 

Sum of the longest diameters of metastases (mm)

61 (46 to 150)

75 (41.5 to 109)

0.697

Number of metastases

17 (6 to 52)

11.5 (5.5 to 28)

0.309

Number of organs with metastasis

2 (1 to 2)

2 (1 to 2)

0.899

Peritoneal dissemination

2 (13.3%)

7 (16.7%)

1.00

Total lines of chemotherapy

2 (2 to 3)

2 (1 to 3)

1.00

Use or any molecular target agents

13 (86.7%)

37 (88.1%)

1.00

Bevacizumab

12 (80.0%)

33 (78.6%)

1.00

Cetuximab and/or panitumumab*

6 (100%)

16 (66.7%)

0.155

Use of oxaliplatine combination

14 (93.3%)

36 (85.7%)

0.66

Use irinotecan combination

12 (80.0%)

26 (61.9%)

0.339

Conversion

1 (6.7%)

0 (0%)

0.263

  1. USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. BMI: body mass index. ASA score: American Society of Anesthesiologists score. KRAS: Kirsten rat sarcoma viral oncogene. CEA: carcinoembryonic antigen. Variables were statistically analyzed by Wilcoxon’s rank-sum test (quantitative variables), Fisher’s exact test (categorical, binary) or Chi-square test (categorical, more than three variables). *Use of cetuximab and/or panitumumab was presented as frequency in the KRAS exon 2 wild-type tumor only.